超声造影与增强CT评估TACE治疗原发性肝癌疗效的价值对比

doi:10.3969/j.issn.1006-6233.2018.07.014

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (1687 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To comparatively analyze the value of contrast-enhanced ultrasound and enhanced CT in evaluating the curative effect of transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods: 70 patients with primary liver cancer treated by TACE in the hospital from January 2015 to December 2017 were selected as the subjects. All patients were examined by contrast-enhanced ultrasound, enhanced CT and digital subtraction angiography (DSA) at 1 month after operation. With DSA as the golden standard, the sensitivity, specificity and accuracy of contrast-enhanced ultrasound and enhanced CT in evaluating the curative effect of TACE were compared. Results: DSA showed 63 residual lesions (positive) and 31 negative lesions. With DSA as the golden standard, the sensitivity, specificity and accuracy of contrast-enhanced ultrasound in the diagnosis of residual lesions(positive) (95.24%,100.00%and 96.81%) were significantly higher than those of enhanced CT (84.13%,100.00%and 89.36%) (P<0.05). Conclusion: Compared with contrast-enhanced CT, the sensitivity and accuracy of contrast-enhanced ultrasound are significantly higher in diagnosing residual lesions after TACE for primary liver cancer. It is an effective method for evaluating the curative effect of TACE in the treatment of primary liver cancer.

Key words： Ultrasound contrast Enhanced CT Transcatheter arterial chemoembolization Primary carcinoma of liver

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.07.014 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I7/1113

[1] Feng MU,Schipper MJ,Balter JM,et al.A phase 2 trial of individualized adaptive stereotactic body radiation therapy(SBRT)for patients at high risk for liver damage[J].Int Radiat Oncol Biol Phys,2013,87(2):s27.
[2] Hennedige T,Venkatesh S K.Imaging of hepatocellular carcinoma:diagnosis,staging and treatment monitoring[J].Cancer Imaging,2013,12(3):530~547.
[3] 陈刚,唐晓军,魏强,等.超声造影评价肝动脉化疗栓塞联合微波消融治疗中晚期肝癌疗效[J].东南国防医药,2016,18(5):531~533,539.
[4] 乔彬彬,虞希祥,王舒婷,等.TACE术中灌注氟尿嘧啶、奥沙利铂及吡柔比星治疗原发性肝癌的临床效果分析[J].介入放射学杂志,2015,24(4):349~353.
[5] 敖劲,曾令雯,刘衡,等.原发性肝癌DSA表现与TACE疗效的关系分析[J].中国普通外科杂志,2016,25(1):51~56.
[6] 张大福,李振辉,杨光军,等.新型双能CT融合技术对肝癌TACE术后的评估[J].中国临床医学影像杂志,2016,27(8):557~561.
[7] 孙伟,李忱瑞.CT对肝癌TACE术后疗效及其残灶活性的评估作用分析[J].中国CT和MRI杂志,2015,13(5):77~79,106.
[8] 曾春.DWI联合CT增强扫描在评估TACE治疗肝癌患者的临床价值[J].中国CT和MRI杂志,2016,14(4):80~83.
[9] 余炎,吕君,余祖江,等.四种影像学检查评价原发性肝癌患者介入治疗的疗效[J].实用肝脏病杂志,2017,20(2):199~202.
[10] 黄崑,刘艳君,王学梅,等.超声造影与增强CT在评价肝癌行TACE后疗效的对照研究[J].现代肿瘤医学,2015,23(18):2670~2672,2673.
[11] 贵传玲.超声造影技术对原发性肝癌介入治疗效果的评估价值[J].山东医药,2016,56(33):86~88.
[12] 王海军,程瑞洪,王朝晖,等.超声造影在肝动脉化疗栓塞术联合微波消融治疗肝癌效果评估中的应用[J].北华大学学报(自然科学版),2017,18(5):645~648.
[13] Liu G J,Wang W,Lu M D,et al.Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J].Liver Cancer,2015,4(4):241~252.
[14] 王金岩,乌日丽其,庞芳,等.实时超声造影应用于肝恶性肿瘤微创治疗的临床价值[J].疾病监测与控制,2015,9(1):51~52.